Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 531Squamous Cell Carcinoma of Head and Neck 273Head and Neck Neoplasms 252Lung Neoplasms 238Uterine Cervical Neoplasms 176Stomach Neoplasms 168Esophageal Neoplasms 160Nasopharyngeal Carcinoma 123Urinary Bladder Neoplasms 116Esophageal Squamous Cell Carcinoma 114Neoplasms 113Small Cell Lung Carcinoma 103Breast Neoplasms 92Ovarian Neoplasms 89Neoplasm Metastasis 89Carcinoma, Squamous Cell 76Cholangiocarcinoma 75Pancreatic Neoplasms 71Biliary Tract Neoplasms 69Mesothelioma, Malignant 57Oropharyngeal Neoplasms 56Carcinoma 55Adenocarcinoma Of Esophagus 52Recurrence 47Parkinson Disease 4, Autosomal Dominant Lewy Body 47Carcinoma, Ovarian Epithelial 45Nasopharyngeal Neoplasms 41Lymphoma 41Adenocarcinoma of Lung 41Gallbladder Neoplasms 38

Interventions

Lenalidomide 4Gemcitabine 4Dexamethasone 4Cyclophosphamide 4Bortezomib 4Nivolumab 3Cisplatin 3Carboplatin 3vandetanib 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2pomalidomide 2pembrolizumab 2liposomal doxorubicin 2fludarabine 2durvalumab 2capivasertib 2Paclitaxel 2Doxorubicin 2Bevacizumab 2venetoclax 1umbralisib 1ublituximab 1tremelimumab 1tivozanib 1ricolinostat 1regorafenib 1pazopanib 1niraparib 1nilotinib 1neratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Disease Progression × Cisplatin × Clear all
NCT05712356 2026-05-26

BOLSTER

Lisata Therapeutics, Inc.

Phase 2 Terminated
66 enrolled 12 charts
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Disease Progression

NCT07274384 2025-12-10

HYPERBOLIC

Università Vita-Salute San Raffaele

Phase 2 Not yet recruiting
74 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Disease Progression

NCT07008716 2025-06-06

Omitting CTV for Primary Tumor in LS-SCLC

Sun Yat-sen University

Phase 3 Recruiting
852 enrolled

Radiation Injuries, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡